文献速递肾移植

再灌注后肾移植活检可预测单肾移植结局:中国10年观察性研究

Postreperfusion Renal Allograft Biopsy Predicts Outcome of Single-Kidney Transplantation: A 10-Year Observational Study in China.
PubMed 文献 · Kidney Int Rep · 2023-10-29

该研究回顾性分析461例2010至2017年死亡供者单肾移植的再灌注活检标本,由经验丰富的肾病理学家判读,中位随访6.8年。结果显示Remuzzi评分与死亡删失的移植物失败独立相关(每增加1分HR 1.389,95%CI 1.181-1.633,P<0.001),且供肾获取活检与再灌注活检的组织学一致性低(kappa=0.137)。

要点

  • 高Remuzzi评分供肾来自更老、高血压更多、KDRI更高的供者。
  • 供肾获取活检与再灌注活检的组织学一致性低(kappa=0.137)。

核心结论

  • 再灌注活检组织学与死亡供者移植后的长期移植物结局相关。
  • 供肾获取活检与再灌注活检的组织学一致性低。

研究设计与样本

  • 回顾性观察性研究,纳入2010至2017年461例死亡供者单肾移植的再灌注活检标本。
  • 由经验丰富的肾病理学家判读组织学,中位随访6.8年(范围0.2-11.9年)。
  • 采用Remuzzi评分(0-12分)分为低分(≤3)和高分(>3)组,并进行时间至事件分析。

主要发现

  • 高Remuzzi评分供肾来自更老供者,且高血压、终末肌酐更高、脑血管病死亡、扩大标准供者及KDRI更高的发生率更高(均P<0.001)。
  • 调整分析中,Remuzzi评分与死亡删失移植物失败独立相关(每增加1分HR 1.389,95%CI 1.181-1.633,P<0.001)。
  • 供肾获取活检与再灌注活检的总体组织学一致性kappa=0.137。

关键数值与推荐

  • Remuzzi评分量表为0-12分,低分组≤3分,高分组>3分。
  • Remuzzi评分每增加1分,死亡删失移植物失败HR为1.389(95%CI 1.181-1.633,P<0.001)。
  • 供肾获取活检与再灌注活检的组织学一致性kappa=0.137。

临床怎么用

  • 再灌注活检Remuzzi评分可用于评估死亡供者单肾移植的长期移植物失败风险。
  • 供肾获取活检与再灌注活检一致性低,提示需优化获取活检实践。

局限性

  • 本研究为回顾性观察性研究。
  • 需要前瞻性试验来优化获取活检实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Biopsy findings often lead to the discard of many donor kidneys although their clinical value is not fully understood. We investigated the predictive value of postreperfusion biopsy on long-term allograft outcome after single-kidney transplantation. METHODS: We retrospectively evaluated the significance of histologic findings, read by experienced renal pathologists, in 461 postreperfusion biopsy specimens collected from 2010 to 2017 after deceased donor renal transplant; and performed time-to-event analyses to determine the association between histology and hazard of death-censored graft failure. Recipients were followed-up with over a median time of 6.8 (range, 0.2-11.9) years. We assessed specimens using the Remuzzi score (scale of 0-12) and categorized them into low-score (≤3) and high-score (>3) groups. Kappa coefficients were calculated to assess agreement in procurement versus reperfusion biopsies. RESULTS: High Remuzzi score kidneys came from older donors with a higher incidence of hypertension, higher final creatinine, death from cerebrovascular disease, expanded criteria donor, and a higher kidney donor risk index (KDRI) (all P < 0.001). In adjusted analyses, Remuzzi score was independently associated with death-censored graft failure (hazard ratio [HR] 1.389 for each 1 score rise in Remuzzi score, 95% confidence interval 1.181-1.633, P < 0.001). Overall histologic agreement (procurement biopsy versus reperfusion biopsy) was kappa = 0.137. CONCLUSION: Our findings suggest that postreperfusion biopsy is associated with long-time graft outcomes after transplant from a deceased donor. Agreement between procurement and reperfusion biopsy was found to be low. Prospective trials are necessary to optimize procurement biopsy practices.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Wang M, Lv J, Zhao J, et al. Postreperfusion Renal Allograft Biopsy Predicts Outcome of Single-Kidney Transplantation: A 10-Year Observational Study in China. Kidney Int Rep. 2023. PMID: 38312778. doi:10.1016/j.ekir.2023.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。